Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge. Cancers 2022, 14: 1931. PMID: 35454838, PMCID: PMC9027936, DOI: 10.3390/cancers14081931.Peer-Reviewed Original ResearchMechanisms of resistanceNon-small cell lung cancerEGFR-mutant tumorsPercentage of non-small cell lung cancerCell lung cancerMultiple mechanisms of resistanceEGFR tumorsPotential therapeutic strategyClinical benefitToxicity profileTreatment optionsLung cancerFrequent alterationsTherapeutic strategiesAcquired mechanismsOsimertinibTumorMultiple mechanismsTreatmentEGFRIncreased useCancer